6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s232, 2023. DOI: 10.25251/skin.7.supp.232. Disponível em: https://skin.dermsquared.com/skin/article/view/2337. Acesso em: 18 may. 2025.